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for the organisation and delivery of health services and medical
care lies with the authorities of the Member States, with support
from the EU where necessary [1]. One key way that Union
action can add value is by providing health-related data that
are comparable between countries of the EU. This allows
benchmarking, enabling authorities and health professionals to
see how they are doing in comparison to best practice and to
identify where they might turn to learn lessons.
The article published Mehta et al. [2] in this issue of the
Journal of Cystic Fibrosis shows both the potential value of
such data, and the challenges involved in providing them.
Behind the simple collection of data lies the meticulous work of
years to ensure that the underlying meanings to those numbers
are also comparable, which is both the challenge and the key
added value of comparing data at the European level. Yet once
it is done, the results presented by Mehta et al. [2] provide
evidence of a specific gap in outcomes for children with cystic
fibrosis between different countries across Europe.
This highlights the potential of such data in the specific
European context. Across the EU we have the largest collective
commitment to universal access to high-quality healthcare on
the basis of equity and solidarity anywhere in the world [3]. Yet
although the aims are the same, the methods are very different.
This ‘natural laboratory’ provides enormous opportunities for
learning from each other, and for improving the health systems
throughout Europe.
For authorities to take action such as changing programmes
and resources, however, the data provided needs to be not just
relevant, but rigorous in its reliability, validity and compara-
bility. Achieving this for comparable data at the European level⁎ Tel.: +352 4301 38816; fax: +352 4301 31050.
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case, and indeed often requires focusing on a smaller set of
comparable data which are nevertheless enough to provide
insights such as the comparisons set out here. These can then
be complemented with more contextual data within specific
systems and settings, as part of the process of understanding the
message behind the comparisons.
When such comparisons and their analysis do identify a need
for action, this raises the question of how to respond. Rare
diseases present particular challenges for health professionals
and public authorities, not only in terms of limited resources but
also in terms of the scarcity of expertise in how best to respond
to them. This is the case in this particular instance, as Mehta
et al. [2] make clear, with relatively affordable treatments
available. There is clear potential for added value through
cooperation at European level, through which knowledge and
expertise can be pooled and best practice identified.
In order to help realise this potential, the European
Commission has set out a European strategy for rare diseases
[4] focusing on improving recognition and visibility of rare
diseases, supporting policies on rare diseases in the Member
States and developing European cooperation, coordination and
regulation for rare diseases (including in particular substantial
funding for research into rare diseases [5], and a supportive
specific licensing regime for orphan drugs [6]).
The EU Council of Ministers has also adopted a Recom-
mendation [7] on rare diseases, which represents a political
commitment of EU Member States to establishing national
action plans for rare diseases by 2013 at the latest. The
ORPHANET database [8] provides a practical pooling of
knowledge and contacts on rare diseases. And the Commission
is funding pilot ‘European Reference Networks’ on specific
diseases with the aim of bringing together existing expertise,
facilitating treatment for patients and facilitating further
research, including ECORN-CF [9] for cystic fibrosis.d by Elsevier B.V. All rights reserved.
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support to EU Member States, the primary challenge remains
the development of health systems within each country.
McCormick et al. [10] have shown the potential link between
resources available for health within countries and survival
rates for cystic fibrosis, comparing EU and non-EU countries in
2003. Ten of the countries identified in McCormick et al. [10]
as non-EU countries have since joined the Union [11], and have
potential access to substantial investment through the EU struc-
tural funds.
The priorities for the use of these funds within each Member
State are set by the countries themselves. Yet although health is
one of the potential areas for this large-scale EU investment,
relatively little use has been made of this possibility, with
specific investment in health representing only around 1.5% of
the current funds available [12]. Amongst the many competing
claims for investment, it seems to have been difficult to make
the case for investment in health. Given the difficulty of
establishing clear comparisons, it is rare to have detailed com-
parative data that can rigorously identify where there are gaps
that require investment to fill.
This work by Mehta et al. [2] does in fact provide such data
which have been sent to each participating country. The sen-
sitivity of the findings is understandable given that the data
imply the premature death of children affected by an inherited
disease that is amenable to therapy. Nevertheless, the full value
will only be realised once all the individual countries are able
to be identified and the comparisons between them can there-
fore be made publicly. If this transparency can be agreed and
published, it will provide a key basis for making specific
progress on the equitable delivery of services for people with
cystic fibrosis across the European Union.
Finally, as Mehta et al. [2] state, a reliable tool for this
purpose may be the comparison of childhood outcomes for
the most commonly inherited form of this disease. As more
countries screen for cystic fibrosis at birth, we could profoundlyincrease our understanding of the nature versus nurture debate
using cystic fibrosis as a paradigm for treatable inherited
diseases more widely.References
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